RxDoctor Payments DataLook up a doctor →

Winston Shipley, MD

Neurology · Oklahoma City, OKNPI 1154393163

Payments from drug & device makers

$10,629in general payments, 2019–2025

Across 790 payments — averaging $13.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novartis$1K
  • Supernus Pharmaceuticals, Inc.$609
  • Sanofi$471
  • Acadia Pharmaceuticals Inc$433
  • Biogen$392
  • plus $5K from 47 others

What the payments were for

  • Speaking & faculty fees$741%
  • Food & beverage$10,50899%
  • Education$470%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$10,629 in reported general payments places this provider in the 65th percentile of 152 neurology providers in Oklahoma.

See all neurology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$143,745
Medicare patients
905
Services billed
1,411

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine13$109,214
RytaryCarbidopa/Levodopa62$101,022
CopaxoneGlatiramer Acetate13$74,255
AptiomEslicarbazepine Acetate14$41,306
VimpatLacosamide23$31,582
Nurtec OdtRimegepant Sulfate15$26,876
Glatiramer Acetate18$25,022
Lacosamide168$24,146
Levetiracetam574$20,529
Memantine Hcl533$19,204
Levetiracetam ErLevetiracetam90$13,995
Carbamazepine ErCarbamazepine65$12,102
Carbidopa-LevodopaCarbidopa/Levodopa298$11,516
DilantinPhenytoin Sodium Extended28$8,559
Donepezil Hcl506$7,327

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo, Copaxone$186$183,46926 claims
Amneal Pharmaceuticals LLCRytary$89$101,02262 claims
Sunovion Pharmaceuticals Inc.Aptiom$378$41,30614 claims
PfizerNurtec Odt, Dilantin$270$35,43443 claims
UCB, Inc.Vimpat$345$31,58223 claims
Upsher-smith Laboratories LLCTopiramate$37$65872 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 152 neurology providers in Oklahoma.

Other neurology in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →